Edition:
India

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

78.97CNY
22 Jun 2018
Change (% chg)

¥0.78 (+1.00%)
Prev Close
¥78.19
Open
¥77.10
Day's High
¥79.29
Day's Low
¥76.20
Volume
20,143,400
Avg. Vol
17,893,401
52-wk High
¥83.29
52-wk Low
¥37.24

Chart for

About

JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty... (more)

Overall

Beta: 0.50
Market Cap(Mil.): ¥168,815.80
Shares Outstanding(Mil.): 2,816.88
Dividend: 0.11
Yield (%): 0.19

Financials

  600276.SS Industry Sector
P/E (TTM): 59.17 30.95 32.74
EPS (TTM): 1.01 -- --
ROI: 23.31 14.84 14.38
ROE: 23.04 16.34 16.08

BRIEF-Jiangsu Hengrui Medicine unit passes U.S. FDA approval

* Says co's unit Shanghai Hengrui Pharmaceutical Co Ltd received FDA approval for desflurane for inhalation (product) from U.S. Food and Drug Administration

02 Mar 2018

BRIEF-Jiangsu Hengrui Medicine receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Health and Youth Care Inspectorate

28 Feb 2018

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

08 Jan 2018

Earnings vs. Estimates